Antiplatelet Effects of Ticlopidine Are Reduced in Experimental Hypercholesterolemia

 

PDF Download Buy Article Permissions and Reprints

Summary

This study determines the antiplatelet effects of oral ticlopidine (100 mg/kg × day) in experimental hypercholesterolemia. Rabbits were fed either a standard diet or a cholesterol-enriched diet (0.5% for 3 months, 1% for 1 month). In normocholesterolemic controls ADP-, but not collagen-induced platelet aggregation was inhibited by ticlopidine treatment. This was accompanied by a significantly enhanced inhibition of ADP-induced platelet aggregation and stimulation of cyclic AMP accumulation by iloprost. Hypercholesterolemia considerably attenuated the inhibition of ADP-induced aggregation by ticlopidine but did not change its effect on the iloprost-induced inhibition of platelet function and cyclic AMP formation. ADP-induced platelet-derived Llnumbuxane formation was considerably greater in hypercholesterolemic rabbits and not reduced by ticlopidine. Ticlopidine did also not significantly influence the extent and severity of atherosclerotic plaque formation although a tendency for improvement was observed in a subgroup of animals. The data suggest that hypercholesterolemia attenuates the inhibitory effect of ticlopidine on A DP-induced platelet aggregation. This might be related to the stimulation of thromboxane formation by ADP in hypercholesterolemia. The maintained protection from ADP-induced inhibition of cAMP accumulation suggests a minor role of this mechanism in the progression of hypercholesterolemia-induced vessel disease in this model.

• References

• 1 Carvalho AC A, Colman RW, Lees RS. Platelet function in hyperlipoproteinemia. N Engl J Med 1974; 290: 434-8
  CrossrefPubMedGoogle Scholar
• 2 Schrör K. Platelet reactivity and arachidonic acid metabolism in type IJ hyperlipoproteinemia and its modification by cholesterol-lowering agents. Eicosanoids 1990; 3: 67-72
  PubMedGoogle Scholar
• 3 Croft DK, Beilin LJ, Vandongen R, Rouse I, Masarei J. Leukocyte and platelet function and eicosanoid production in subjects with hypercholesterolemia. Atherosclerosis 1990; 83: 101-9
  CrossrefPubMedGoogle Scholar
• 4 Ross R. The pathogenesis of atherosclerosis – An update. N Engl J Med 1986; 314: 488-500
  CrossrefPubMedGoogle Scholar
• 5 Curtiss LK, Black AS, Takagi Y, Plow EF. New mechanism for foam cell generation in atherosclerotic lesions. J Clin Invest 1987; 80: 367-73
  CrossrefPubMedGoogle Scholar
• 6 Moore S, Friedman RJ, Singal DP, Gauldie J, Blajchman MA, Roberts RS. Inhibition of injury-induced thromboatherosclerotic lesions by antiplatelet serum in rabbits. Thromb Haemost 1976; 35: 70-81
  Article in Thieme ConnectPubMedGoogle Scholar
• 7 Harker LA, Harlan JM, Ross R. Effect of sulfinpyrazone on homocysteine-induced endothelial injury and atherosclerosis in baboons. Circ Res 1983; 53: 731-9
  CrossrefPubMedGoogle Scholar
• 8 Kristcnsen SD, Roberts KM, Kishk YT, Martin JF. Accelerated atherogenesis occurs following platelet destruction and increases in mcgacaryocytc size and DNA content. Eur J Clin Invest 1990; 20: 239-47
  PubMedGoogle Scholar
• 9 Bailey JM, Makheja AN, Butler J, Salata K. Antiinflammatory drugs in experimental atherosclerosis. Atherosclerosis 1979; 32: 195-203
  CrossrefPubMedGoogle Scholar
• 10 Jouve R, Juhan-Vague I, Aillaud M-F, Sermcnt-Jouve M-P, Payan H. Comparison of the effects of aspirin and indomcthacin on aortic atherogenesis induced in rabbits. Atherosclerosis 1982; 42: 319-22
  CrossrefPubMedGoogle Scholar
• 11 Chyattc D, Chen TL. Patterns of failure of aspirin treatment in symptomatic atherosclerotic carotid artery disease. Neurosurgery 1990; 26: 565-9
  CrossrefPubMedGoogle Scholar
• 12 Sun Y-P, Zhu B-Q, Sievers RE, Isenberg WM, Parmley WW. Aspirin inhibits platelet activity but does not attenuate experimental atherosclerosis. Am Heart J 1993; 125: 79-86
  CrossrefPubMedGoogle Scholar
• 13 Debons AF, Fani K, Jimenez FA. Enhancement of experimental atherosclerosis by aspirin. J Toxicol Environ Health 1981; 8: 899-906
  CrossrefPubMedGoogle Scholar
• 14 Moake JL, Turner NA, Stathopoulos NA, Nolasco L, Heliums JD. Shear-induced platelet aggregation can be mediated by VWF released from platelets, as well as by exogenous large or unusually large VWF-multimcrs, requires adenosine diphosphate, and resistant to aspirin. Blood 1988; 71: 1366-74
  PubMedGoogle Scholar
• 15 Rajagopalan S, Mc Intyre LV, Hall ER, Wu KK. The stimulation of arachidonic acid metabolism in human platelets by hydrodynamic forces. Biochim Biophys Acta 1988; 958: 108-15
  CrossrefPubMedGoogle Scholar
• 16 Defrcyn G, Bernat A, Delebassee D, Maffrand JP. Pharmacology of ticlopidine: A review. Semin Thromb Hemost 1989; 15: 159-66
  Article in Thieme ConnectPubMedGoogle Scholar
• 17 Schror K. The basic pharmacology of ticlopidine and clopidogrel. Platelets 1993; 4: 252-61
  CrossrefPubMedGoogle Scholar
• 18 Samama ChM, Bonnin Ph, Bonneau M, Pignaud G, Mazoyer E, Baillart O, Maffrand JP, Viars P, Caen JP, Drouet LO. Comparative arterial antithrombotic activity of clopidogrel and acetyl salicylic acid in the mg. Thromb Haemost 1992; 68: 500-5
  Article in Thieme ConnectPubMedGoogle Scholar
• 19 Defrcyn G, Gachet C, Savi P, Driot F, Cazcnavc JP, Maffrand JP. Ticlopidine and clopidogrel (SR 25990C) selectively neutralize ADP inhibition of PGE₁-activated platelet adenylate cyclase in rats and rabbits. Thromb Haemost 1991; 65: 186-90
  Article in Thieme ConnectPubMedGoogle Scholar
• 20 Reece AH, Walton PL. Inhibition of intimal proliferation of rabbit aorta by ticlopidine (Abstract 0873). Thromb Haemost 1979; 42: 367
  PubMedGoogle Scholar
• 21 Friedman RJ, Stcmerman MB, Wenz B, Moore S, Gauldie J, Gent M, Tiell ML, Spaet TH. The effect of thrombocytopenia on experimental atherosclerotic lesion formation in rabbits. J Clin Invest 1977; 60: 1191-201
  CrossrefPubMedGoogle Scholar
• 22 Löbel P, Schrör K. Stimulation of vascular prostacyclin and inhibition of platelet function by oral defibrotide in cholesterol-fed rabbits. Atherosclerosis 1989; 80: 69-79
  CrossrefPubMedGoogle Scholar
• 23 Weber A-A, Hohlfcld Th, Strobach H, Schror K. Oral naftidrofurvl prevents platelet hyperreactivity ex vivo and inhibits functional desensitization to prostacyclin in hypercholesterolemia. J Cardiovasc Pharmacol 1993; 21: 332-8
  CrossrefPubMedGoogle Scholar
• 24 Schror K, Seidel H. Blood-vessel wall arachidonate metabolism and its pharmacological modification in a new in vitro assay system. Naunyn Schmiedeberg’s Arch Pharmacol 1988; 337: 177-82
  PubMedGoogle Scholar
• 25 Cristalli G, Mills DC B. Identification of a receptor for ADP on blood platelets by photoaffinity labelling. Biochem J 1993; 291: 875-81
  CrossrefPubMedGoogle Scholar
• 26 Hass WK, Easton JD, Adams jr HP, Prysc-Phillips W, Molony BA, Anderson S, Kamm B. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: 501-7
  CrossrefPubMedGoogle Scholar
• 27 Savi P, Herbert JM, Pflieger AM, Dol F, Delebassee D, Combalbert J, Defreyn G, Maffrand JP. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 1992; 44: 527-32
  CrossrefPubMedGoogle Scholar
• 28 Hohlfeld Th, Weber A, Schror K. Oral cicaprost reduces platelet and neutrophil activation in experimental hypercholesterolemia. In: Prostaglandins in the cardiovascular system. Sinzinger H, Schror K. (eds) Basel: Birkhauser; Agents Actions 1992. (; 37). (Suppl) 289-96
  Google Scholar
• 29 Martin JF, Slater DN, Kishk YT, Trowbridge EA. Platelet and megakaryocyte changes in cholesterol-induced experimental atherosclerosis. Arteriosclerosis 1985; 5: 604-12
  CrossrefPubMedGoogle Scholar
• 30 Weber A, Hohlfeld Th, Schror K. ADP-induced second wave aggregation in platelet rich plasma from hypercholesterolemic rabbits. Thromb Res 1991; 64: 703-12
  CrossrefPubMedGoogle Scholar
• 31 Dalai KB, Ebbe S, Mazoyer E, Carpenter D, Yee T. Biochemical and functional abnormalities in hypercholesterolemic rabbit platelets. Lipids 1990; 25: 86-92
  CrossrefPubMedGoogle Scholar
• 32 Sweatt DJ, Blair IA, Cragoe EJ, Limbird LE. Inhibitors of Na⁺/H⁺ exchange block epinephrine- and ADP-induced stimulation of human platelet phospholipase C by blockade of arachidonic acid release at a prior step. J Biol Chem 1986; 261: 8660-6
  PubMedGoogle Scholar
• 33 Packham MA, Kinlough-Rathbone RL, Mustard JF. Thromboxane A₂ causes feedback amplification involving extensive thromboxane A ₂formation upon close contact of human platelets in media with a low concentration of ionized calcium. Blood 1987; 70: 647-51
  PubMedGoogle Scholar
• 34 Packham MA, Bryant NL, Guccione MA, Kinlough-Rathbone RL, Mustard JF. Effect of the concentration of Ca²⁺ in the suspending medium on the responses of human and rabbit platelets to aggregation agents. Thromb Haemost 1989; 62: 968-76
  Article in Thieme ConnectPubMedGoogle Scholar
• 35 Sage SO, Heemskerk JW M. Thromboxane receptor stimulation inhibits adenylate cyclase and reduces cyclic AMP-mediated inhibition of ADP-evoked responses in fura-2-loaded human platelets. FEBS Lett 1992; 298: 199-202
  CrossrefPubMedGoogle Scholar